Lars Kjeldsen
Overview
Explore the profile of Lars Kjeldsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
1650
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schovsbo J, Kjeldsen L, Norskov K, Sengelov H, Kornblit B, Schjodt I, et al.
Transplant Cell Ther
. 2024 Nov;
31(1):28.e1-28.e10.
PMID: 39522721
Allogenic hematopoietic cell transplantation (allo-HCT) with myeloablative conditioning traditionally requires 30 days of hospitalization after stem cell infusion. However, advancements in supportive and prophylactic care have allowed for a trend...
2.
Nielsen I, Tolver A, Piil K, Kjeldsen L, Gronbaek K, Jarden M
Eur J Oncol Nurs
. 2024 Mar;
69:102538.
PMID: 38457934
Objective: To investigate the quality of life (QoL) and the impact of caregiving in family caregivers of hematological cancer patients and its association with patient symptom burden. Methods: A cross-sectional...
3.
Brieghel C, da Cunha-Bang C, Mourek J, Kjeldsen L, Niemann C
Blood Adv
. 2024 Mar;
8(16):4449-4456.
PMID: 38429090
Approximately half of patients with chronic lymphocytic leukemia (CLL) will never require treatment; nonetheless, they are recommended life-long specialized follow-up (sFU). To prioritize health care resources, local hospital management implemented...
4.
Copland M, Ariti C, Thomas I, Upton L, Sydenham M, Mehta P, et al.
Br J Haematol
. 2023 Nov;
204(3):871-876.
PMID: 38016651
Improving outcomes for older patients with acute myeloid leukaemia remains an unmet need. As part of the LI-1 trial, we evaluated lenalidomide (LEN) in combination with low-dose cytosine arabinoside (LDAC)...
5.
Nielsen I, Piil K, Tolver A, Gronbaek K, Kjeldsen L, Jarden M
Support Care Cancer
. 2022 May;
30(8):6923-6935.
PMID: 35543814
Purpose: This study investigated the feasibility of a one-on-one peer support intervention in family caregivers of newly diagnosed patients with a hematological cancer during initial treatment. Methods: The study was...
6.
Russell N, Hills R, Kjeldsen L, Clark R, Ali S, Cahalin P, et al.
Br J Haematol
. 2022 Apr;
198(3):528-534.
PMID: 35388465
The prognosis for younger patients with relapsed acute myeloid leukaemia (AML) is generally dismal. Allogeneic stem cell transplantation is the preferred therapy for these patients. As part of the UK...
7.
Nielsen I, Piil K, Gronbaek K, Kjeldsen L, Jarden M
Cancer Nurs
. 2022 Jan;
45(5):E801-E809.
PMID: 35067578
Background: Family caregivers play a vital role in providing care and support for patients with life-threatening hematologic diseases. Extensive patient care needs and long-term treatment trajectories can negatively affect the...
8.
Russell N, Hills R, Kjeldsen L, Dennis M, Burnett A
Br J Haematol
. 2021 Dec;
196(6):1344-1347.
PMID: 34904225
Secondary acute myeloid leukaemia (AML) has a poor outcome following "3 + 7-like" chemotherapy. While CPX-351 has been approved for patients aged 60-75, the optimal treatment, or comparator, in younger...
9.
Norskov K, Fridthjof K, Kampmann P, Dunweber A, Andersen C, Renaberg T, et al.
Leuk Res
. 2021 Nov;
112:106756.
PMID: 34839055
Technological advances have made it possible to offer home-based chemotherapy to patients without health care professionals being present. Prior studies on effects of home-based treatment lack inclusion of patients with...
10.
Russell N, Hills R, Thomas A, Thomas I, Kjeldsen L, Dennis M, et al.
Haematologica
. 2021 Oct;
107(7):1518-1527.
PMID: 34647442
Reduced intensity conditioning (RIC) transplantation is increasingly offered to older patients with acute myeloblastic leukemia. We have previously shown that a RIC allograft, particularly from a sibling donor, is beneficial...